ASH 2022 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, Myeloma, VideosDecember 12, 2022
Join MPE’s webinar on Access Barriers to Clinical Trials in CEE CountriesAccess, MPEOctober 20, 2022
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, MyelomaAugust 30, 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
